このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AtriCure 将来の成長

Future 基準チェック /16

AtriCure利益と収益がそれぞれ年間19.2%と12.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-6.2% 20.5%なると予測されています。

主要情報

19.2%

収益成長率

20.5%

EPS成長率

Medical Equipment 収益成長	16.6%
収益成長率	12.8%
将来の株主資本利益率	-6.2%
アナリストカバレッジ	Good
最終更新日	29 May 2024

今後の成長に関する最新情報

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18

Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Jan 20

業績と収益の成長予測

NasdaqGM:ATRC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	594	-21	26	44	7
12/31/2025	526	-29	10	26	9
12/31/2024	462	-37	-1	12	9
3/31/2024	415	-37	-25	-12	N/A
12/31/2023	399	-30	-8	4	N/A
9/30/2023	381	-25	-13	1	N/A
6/30/2023	366	-28	-48	-3	N/A
3/31/2023	349	-38	-18	-2	N/A
12/31/2022	330	-46	-39	-22	N/A
9/30/2022	316	-56	-37	-22	N/A
6/30/2022	303	53	-32	-20	N/A
3/31/2022	290	52	-41	-29	N/A
12/31/2021	274	50	-24	-14	N/A
9/30/2021	259	45	-18	-10	N/A
6/30/2021	243	-57	-14	-6	N/A
3/31/2021	213	-49	-18	-13	N/A
12/31/2020	207	-48	-25	-20	N/A
9/30/2020	210	-46	-36	-27	N/A
6/30/2020	212	-50	-44	-34	N/A
3/31/2020	230	-46	-31	-18	N/A
12/31/2019	231	-35	-28	-16	N/A
9/30/2019	222	-23	-20	-11	N/A
6/30/2019	216	-20	-11	-3	N/A
3/31/2019	209	-17	-14	-8	N/A
12/31/2018	202	-21	-10	-4	N/A
9/30/2018	195	-20	-10	-4	N/A
6/30/2018	187	-20	-15	-9	N/A
3/31/2018	180	-27	-16	-9	N/A
12/31/2017	175	-27	N/A	-9	N/A
9/30/2017	170	-33	N/A	-10	N/A
6/30/2017	166	-32	N/A	-9	N/A
3/31/2017	160	-34	N/A	-14	N/A
12/31/2016	155	-33	N/A	-15	N/A
9/30/2016	150	-36	N/A	-20	N/A
6/30/2016	143	-35	N/A	-18	N/A
3/31/2016	135	-32	N/A	-10	N/A
12/31/2015	129	-27	N/A	-8	N/A
9/30/2015	123	-22	N/A	-6	N/A
6/30/2015	118	-16	N/A	-10	N/A
3/31/2015	112	-14	N/A	-16	N/A
12/31/2014	107	-16	N/A	-22	N/A
9/30/2014	99	-16	N/A	-23	N/A
6/30/2014	93	-18	N/A	-21	N/A
3/31/2014	87	-17	N/A	-17	N/A
12/31/2013	81	-11	N/A	-5	N/A
9/30/2013	78	-9	N/A	-2	N/A
6/30/2013	74	-8	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATRC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATRC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ATRC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATRCの収益 ( 12.8% ) US市場 ( 8.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: ATRCの収益 ( 12.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATRC 3 年以内に赤字になると予測されています。

AtriCure 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Atricure, Inc. Provides Earnings Guidance for 2024

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.70 loss

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

AtriCure, Inc., Annual General Meeting, May 13, 2024

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Atricure, Inc. Provides Earnings Guidance for 2024

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Independent Director exercised options to buy US$642k worth of stock.

Insider notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Insider notifies of intention to sell stock

Price target decreased to US$69.50

AtriCure, Inc. to Report Q2, 2022 Results on Aug 02, 2022